by DrKSSMDPhD | October 6, 2017 2:00 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2017/10/tear-sheet-cohbar-industries-cwbr/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
$NOTICKER
Messing up the rhythm of DNA replication may become another addition to the arsenal of cancer therapies in the future according to this Danish study:
http://healthsciences.ku.dk/news/2017/11/researchers-exploit-rhythm-of-dna-replication-to-kill-cancer-cells/
Talking about rhythm, here is to all of you Gummies, wishing each &everyone of you a great day:
https://www.youtube.com/watch?v=N141waS8uq4
Wim.
For those of you on this thread who can’t get the Torrey Hills thread. I got to it by going to the “recent comments”on the upper right of this thread screen and clicking on the “more” of the Torrey Hills comment. Good luck and the best to all the Gummies.
Current portfolio, with percentage of total holdings, in order of decreasing size: APTO 6.8%, PIRS 6.2%, CLRB 6.1%, HALO 6.0%, PTGX 5.7%, AUPH 5.2%, CWBR 5.2%, CAPR 5.1%, STML 5.0%, SRRA 4.5%, ESPR 3.9%, BLPH 3.8%, ARTH 3.6%, SNDX 3.6%, TRIL 3.5%, ONCS 3.1%, AKBA 3.0%, REPH 2.8%, MDGL 2.3%, DERM 2.0%, SCYX 2.0%, AXSM 1.9%, AAVXF 1.0%, “dry powder” 7.7%.
Changes made since last posting: Sold: AKTX, AXSM (decreased), BIOC, CAPR (decreased), RGLS, ZFGN. Bought: AAVXF, CLRB (increased), CWBR, DERM, MDGL, ONCS, PIRS (increased).
I invest only in the biotech sector and I am happy to enjoy the ups and downs of this extremely volatile part of the economy because I am a long-term investor, and only because of Dr. KSS. I would not be investing in any of these stocks without him and I am extremely grateful for the expertise he provides. Thank you, Dr. KSS. Thank you, Cleveland, for all of the work you do to provide financial analyses of these companies.
I could so have a torrid love affair with your portfolio….you know, run off to the Greek Isles with it and be all two-for-the-road in a red ragtop, picnic baskets with champagne. Seriously, very very nice work diplacus. Shrewd weightings too. Like you, I’m now out of RGLS and ZFGN and BIOC and having doubts about AXSM though not out of it yet (small position). Basically you are running the definitive hot biotech ETF, my man. No investing advice intended, but love what I see.
Let me say this about $HALO: it’s not in any of the analyst’s projections here the way it so overtly is with Aurinia, but the central premise of $HALO is that it’s destined for buyout, that it is closing in on a crisis critical-mass type situation a la the OK Corral: lots of astute players with loaded weapons all surrounding PEG-hyaluronidase and needing it to conquer the universe according to their own schemes. Who’s going to draw first? How drawn out will the shooting (bidding war) be? I suspect a review of Helen Torley’s personal ownership of $HALO shares suggests she anticipates something BIG. I think $RHHBY, $MRK, and possibly $BMY are sniffing around. Let me spell it out for you: the new normal for checkpoint inhibitor administration may be to give them almost universally in tandem with PEG-hyaluronidase unless you have a tumor that, by biopsy, is surround by stroma uniquely lean in hyaluronic acid presence.
I think a reasonable takeout price is $20-25B. You can do the rest of the arithmetic. I could be wrong. Anybody can be wrong in biotech. But that number invokes some realistic modeling, people. Can you afford to sit out $HALO when it seriously has to be among the safest plays in biotech right now??? Long.
I admire diplacus’s portion of investable dry powder. I don’t know how much others keep. I think 5-10 percent is rightsize and one should not go less unless you are investing with extreme and unusual conviction. This is a hyperdynamic space and new opportunities are like yellow cabs on Madison Avenue.
Diplacus has committed to much maintenance DD to stay in his picks, but is up to the minute enough that he is making very au courant modifications to portfolio. Very very admirable. He clearly is working at it. They who work at their biotech investing shall be rewarded.
Doc, not to beat the $HALO horse to death, but have your opinions on timing changed since the Q3 conference call? Prior to that, you were thinking potentially Q2 2018, but that was when the ORR data readout was supposed to take place in 2017. Now that it has been pushed to 2018 (2H i think?), do you feel that all the interested players are more likely to wait now until late 2018 or possibly even 2019 to pull the trigger? Thanks Doc!
Hi Mitch: I honestly don’t know but many feel the situation is coming to head and that $MRK is preparing a bid. $HALO
$HALO long.
Implied volatility in HALO options is surging today. I’m not an options trader but the article indicates that is is a harbinger of a large expected move in the underlying stock.
https://finance.yahoo.com/news/implied-volatility-surging-halozyme-therapeutics-134901450.html
Thanks Duck. Very helpful. $HALO long. You might consider reposting this over on the newer Torrey Pines thread, to which I think most have migrated, though this thread is still open.
$Halo long calls
Hi Duck,
Thanks for posting the article. Reading it there isn’t a lot of information in it. Seems like one of those robo-written pieces:”That is because the Dec 15th 2017 $8.00 Put had some of the highest implied volatility of all equity options today.”
That is completely logical because the farther out of the money you go the more expected value is in an option and as a consequence a higher implied volatility. The last time this option traded though was on September 29th. And there is the same bid/ask spread for the put dec $ 16.00.
Best regards, Henno
$noticker
Fantastic portfolio and weighting.
I’ll show you mine since you showed me yours (!); this is the Gummy portion of my portfolio
$ESPR: 16%
$APTO: 13%
$HALO: 12%
$CTEQF: 11% (not bio but a gummy name; thank you HN!)
$MRTX: 8%
$ARTH: 7%
$CWBR: 5%
$ONCS: 5%
$CAPR: 5%
$CLRB: 5%
Cash: 5% (will likely re-enter $TRIL)
Balance: 3 names that my employer won’t let me sell 🙁
Please note that $ESPR, $APTO and $CTEQF are the sizes that they are because of unrealized gains; I still believe in each of them. I recently sold out of $AUPH and reduced $ARTH for names with nearer term catalysts. Will likely re-enter/add to each during 2018. Thank you Dr. KSS for all that you do; my wife’s IRA thanks you!
$ONOV small position
Has anyone had any problems trading this stock? I have a small amount in an account at Zacks and thought I would take advantage of this mornings pop (from ~$.07 to $.11) and close it out to replenish my “dry powder”, but received an error message when attempting to do so. Called Zacks after a 30 minute wait on hold while they tried to figure out why, I was told I am not allowed to sell this via Limit order. Since Zacks told me the going market rate was $.07-something, I decided to continue holding for now. Zacks says this is a new MM rule and they can do nothing for me. I bought this small position via limit order through them, and am dismayed at the prospect of selling it via a market order.
Can anyone shed any light on this? My apologies if this is a stupid question!
(edited to reflect correct brokerage)
$ONOV sp – I can see that the bid is 7 cents and the ask is 11 cents. I am able to put in a limit order with Ameritrade. Of course it will not execute unless I lower to 7 cents. I think you have received a bad explanation is all, there are no current buyers at 11 cents, you could put a limit order in at 6 cents and watch it get executed. It is a bizarre world where a market maker can force you to sell at market.
$ONOV sp
Agreed – I’ve never heard of such a thing… but then I’ve not often traded in such stocks. I was explicitly told I could not place a limit order at ANY price. Period – that it was out of the broker’s hands. Do you think this is erroneous?
$ONOV – NP – That does seem odd. Etrade will only let me place limit orders on OTC stocks, even $CWBR. If I try and do a market order I get this message: Non-equity, bulletin board, OTC, pink sheet and other specific securities are not eligible for the price type you have specified.
If it is the market maker then that should apply to all brokers methinks. I would leave Zacks over such a practice myself.
$ONOV
Clearly, if Zacks cannot make limit orders of OTC stocks, they are in my rear view mirror. They indicated quite clearly though that the restriction stemmed from MMs, NOT themselves and that it was a new rule, enacted about a month ago. I don’t see how this could be kosher, requiring someone to sell a highly volatile stock via market order when the same position was purchased via a limit. I’m a bit upset and relieved this is only a smallish position.
Again, thank you for your thoughts!
$ONOV $Zacktrades trade problem update:
I received an email from Zack’s apologizing for the confusion. As expected, limit orders are completely ok with the proviso that they must remain within the spread for orders less than 10,000 shares. It was not clear if it was ONOV in particular or all OTC stocks. I was able to place a suitable limit order, which the system would not allow yesterday, so they fixed whatever glitch was behind it.
Thank you all for your thoughts and comments – much appreciated!
$ONOV, Hi MeadowBrookManor, We have moved on to the following thread: : https://www.stockgumshoe.com/2017/11/notes-from-torrey-hills-capital-emerging-growth-conference-13-15-november-2017-san-diego-ca/ “Notes from Torrey Hills Capital Emerging Growth Conference, 13-15 November 2017, San Diego, CA” Best2YOU! Always able to locate most recent #ZKSS thread by going to https://www.stockgumshoe.com/author/dr-kss-md-phd/
or by clicking on #ZKSS image in the long hallway to the left of any of HIS posts. Same goes for anyone who has ever created a discussion on stockgumshoe. Click on the image to see his profile page and last thread and last 20 posts. Best2ALL!
Thank you SoGiAm – much obliged!
$CAPR
Another blogger’s perspective on Capricor’s Hope-DMD trial’s 12 month results.
http://alanhobbes.blogspot.sg/2017/11/capricors-12-month-results-brings-hope.html
#Failures – Most of these causes are particularly relevant to #biotech #equities, as well: https://pbs.twimg.com/media/DPZItdQUMAESZ3g.jpg
https://twitter.com/calestous/status/934013920863453184
$CWBR Long… Juvenescence Video
https://youtu.be/vzH3HGk1rIo
$CWBR
Does anyone know if they are still expecting to uplist this year, or is this more likely a first quarter 2018 event?
Uplisting involves meeting qualifications and undergoing a review by NASDAQ. It’s not a totally facile process, and with functionally relatively few working days left this year, it will of necessity not happen before the first quarter.
Not to disagree Dr. but I think there is still time for the uplisting to occur this year.
$CLBR Hopefully the uplisting WILL be this year, but I guess it’s a hard call. Fezziwig on Twitter keeps saying it will be this year. Either way, we’re good. Looking forward to great things from this company next year! Thanks to Doc for the recommendation.
$CWBR ow – NiizaJim 😉 Long #ZKSS &
#Gr8Gummune! #Best2ALL!
Interesting article on anti-aging:
https://www.scientificamerican.com/article/to-stay-young-kill-zombie-cells/
CohBar to list on Nasdaq this Friday!
CohBar Announces Approval for Listing on the NASDAQ Capital Market
NASDAQ Trading to Begin on December 15, 2017 Under Existing Ticker Symbol CWBR
MENLO PARK, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) — CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that The NASDAQ Stock Market LLC has approved the Company’s application to list its common stock on the NASDAQ Capital Market (NASDAQ).
CohBar’s common stock is expected to commence trading on the NASDAQ Capital Market at the opening of trading on December 15, 2017 under the ticker symbol CWBR. The Company’s common stock will continue to trade on the OTCQX until market close on December 14, 2017 under the ticker symbol CWBR. In addition to trading on the NASDAQ Capital Market, the Company’s common stock will also continue to trade on the TSX Venture Exchange under the ticker symbol COB.U.
“Listing on NASDAQ represents a major milestone for our Company and its shareholders, reflecting the significant progress our team has made in preparing CB4211 for clinical trials, and in securing our leadership position in the development of MBTs, a new class of therapeutics with the potential to treat a wide range of age-related diseases,” said Simon Allen, CohBar CEO. “We believe that our NASDAQ listing will significantly enhance our visibility in the marketplace, attract institutional investors, and ultimately help us to realize greater value for our shareholders as we expand our pipeline of novel therapeutics that harness the power of the mitochondria and its encoded peptides.”
CohBar to list on Friday!
CohBar Announces Approval for Listing on the NASDAQ Capital Market
NASDAQ Trading to Begin on December 15, 2017 Under Existing Ticker Symbol CWBR
MENLO PARK, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) — CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that The NASDAQ Stock Market LLC has approved the Company’s application to list its common stock on the NASDAQ Capital Market (NASDAQ).
CohBar’s common stock is expected to commence trading on the NASDAQ Capital Market at the opening of trading on December 15, 2017 under the ticker symbol CWBR. The Company’s common stock will continue to trade on the OTCQX until market close on December 14, 2017 under the ticker symbol CWBR. In addition to trading on the NASDAQ Capital Market, the Company’s common stock will also continue to trade on the TSX Venture Exchange under the ticker symbol COB.U.
“Listing on NASDAQ represents a major milestone for our Company and its shareholders, reflecting the significant progress our team has made in preparing CB4211 for clinical trials, and in securing our leadership position in the development of MBTs, a new class of therapeutics with the potential to treat a wide range of age-related diseases,” said Simon Allen, CohBar CEO. “We believe that our NASDAQ listing will significantly enhance our visibility in the marketplace, attract institutional investors, and ultimately help us to realize greater value for our shareholders as we expand our pipeline of novel therapeutics that harness the power of the mitochondria and its encoded peptides.”
Any insights on Capr which keeps plunging?
Any insight on Capr’s decline?
Everything in biotech sagged today. Biotech funds are being redirected by many into unprecedented yields like FANG stocks. Suspect tide will turn in January.
Thank you. You still believe in this company?
I have a long position in $CAPR. Investing advice not intended.
$RXII NP RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring. “The exploratory endpoint for patient reported outcomes resulted in 88% of the patients indicating that RXI-109 treated scar looked better over control”
Shares down 1%. The financials dont look great and very little insider ownership however the market for a topical on scars would be pretty large even if it wouldn’t be covered by insurance. Anyone else see this as undervalued or at least worth the risk of a small position?
$RXII np – https://www.stockgumshoe.com/2014/12/the-finale-is-grand-the-gain-from-pain-mainly-explained/comment-page-6/#comment-3901953 How ’bout joining the Gummune on the current thread? https://www.stockgumshoe.com/2017/12/special-update-from-arth-ceo-norchi/ #Best2YOU!
I gather you’ve not searched here for prior coverage on this stock $RXII and that you don’t know where the thread now is. This is a low-quality stock not worth investing in. The self-pay market here isn’t what you think. Please join us on the current thread as per Sogiam’s post. It’s always better to know what we’ve said before about a stock before you post…..that’s why certain readers work themselves to death maintaining Gumshoe databases of comments and views. Our views may change, but companies that get off on the wrong foot in biotech commonly stay that way. Like $RXII.
SoGiAM/Dr. KSS I apologize I did do some searching and found posts from 2014 but missed the more blunt/direct remarks SOGiAM linked too. Ill be more diligent searching in the future. Thanks for the confirmation.
$HALO
Baker Bros Advisors Lp increased Halozyme Therapeutics Inc. (HALO) stake by 13.65% reported in 2017Q2 SEC filing. Baker Bros Advisors Lp acquired 189,917 shares as Halozyme Therapeutics Inc. (HALO)’s stock rose 2.38%. The Baker Bros Advisors Lp holds 1.58M shares with $20.27 million value, up from 1.39M last quarter. Halozyme Therapeutics Inc. now has $2.78 billion valuation. The stock decreased 0.05% or $0.01 during the last trading session, reaching $19.68. About 729,692 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since December 19, 2016 and is uptrending. It has outperformed by 28.19% the S&P500.